Kornimate/medical-research-clean huggingface dataset:
machine learning and 3d image-based modeling for real-time body weight and body composition estimation during emergency medical care. study 1

Conditions: Body Weights and Measures; Body Weight in the Overweight and Obese Class - I Population

Summary: the goal of this observational study is to train and validate an ai-driven 3d camera system to estimate total body weight, ideal body weight and lean body weight in male and female adult volunteers of all ages. the main questions this study aims to answer are: * what degree of accuracy of weight estimation can we achieve with an ai-driven 3d camera weight estimation system? * is this accuracy the same in adults of both sexes, all ages, and all body types (underweight, normal weight, overweight)? participants will undergo some anthropometric measurements (height, mid-arm circumference, weight circumference, hip circumference, measured weight), a dxa scan (to measure lean body weight), and 3d imaging using a 3d camera. there will be no interventions.

this study is a single-centre observational study to train, internally validate, and test an ai-driven 3d camera weight estimation system. our hypothesis is that this system, when used in the management of acutely ill patients, will be able to estimate total body weight, ideal body weight, and lean body weight more accurately than other current point-of-care system. healthy volunteers will be used to train and test the system. during a single data collection session of approximately 30 minutes, baseline anthropometric data, a dxa scan, and 3d camera images of volunteers lying on a medical stretcher will be captured. there will be no interventions, and no follow up of participants. the collected data will be used to train an ai algorithm (based on artificial neural networks) to estimate weight using a single depth image. once the ai system is fully evolved, the accuracy of its weight estimation performance will be evaluated in an independent test dataset.

Eligibility criteria:
inclusion criteria: * any willing volunteer. exclusion criteria: * participants with a body weight exceeding the dxa machine capacity \>204kg (450lbs); * pregnant participants; * participants with medical conditions that could confound the study; * participants with any metallic surgical implants; * participants who have had an x-ray with contrast in the past week; * participants who have taken calcium supplements in the 24 hours prior to the study.

Keywords: 3d camera weight estimation computer vision weight estimation
validity of information employed to generate standardized mortality ratios using hospital administrative databases (rnmh)

Conditions: Surgical Condition; Obstetrical Condition; Hospitalization in Acute Care

Summary: in a retrospective cross-sectional study, investigators aimed to valid the variables employed to generate standardized mortality ratio from hospital administrative databases. for this purpose, investigators have compared those variables collected in administrative databases with the information available in patient medical record.


Eligibility criteria:
inclusion criteria: * all inpatients stays in acute care from high mortality diagnosis related groups (drgs) registered in administrative databases of participating hospitals from january to december 2010. exclusion criteria: * hospital participation refusal

Keywords: hospital mortality standardized mortality ratios patient safety healthcare quality hospital performance administrative data
risk factors analysis for clinical important postoperative nausea and vomiting

Conditions: Postoperative Nausea and Vomiting

Summary: postoperative nausea and vomiting (ponv) is a distressing and common complication after surgery. the concept of clinical important ponv (ci-ponv) assesses the impact of ponv on patient-reported outcomes. this research aims to conduct an analysis of the risk factors contributing to ci-ponv utilizing the least absolute shrinkage and selection operator (lasso) and stepwise regression techniques. all 1154 patients participating in the fdp-ponv trial are included in this study and categorized into two groups: the ci-ponv group and the non-ci-ponv group. ci-ponv is defined as the occurrence of ponv with a simplified ponv impact scale score of 5 or higher within 24 hours after surgery. the lasso method is employed to identify the most relevant variables from an initial set of 56 related variables and stepwise regression is used to further refine the selection of the ultimate predictors.a logistic regression model was developed based on the selected factors influencing ciponv. a nomogram was developed as a tool for clinical application.

drawing from prior studies, we conducted a sample size calculation for a predictive model using the website https://mvansmeden.shinyapps.io/beyondepv/. by setting the number of candidate predictors to 9, the events fraction to 0.14, and the criterion value for rmpse to 0.04, we determined that a minimum total sample size of 900 is required, with a minimally expected event per variable of 13.9. all patients were classified into either the ci-ponv group or the non-ci-ponv group. all 56 perioperative clinical features, encompassing baseline characteristics, preoperative conditions, and intraoperative information, were considered as potential predictive factors. in the quest to uncover potential predictive factors associated with ci-ponv, we employed the least absolute shrinkage and selection operator (lasso) to sift through clinically significant variables. subsequently, we utilized stepwise regression based on the akaike information criterion (aic) to further refine the selection of the ultimate predictors. finally, a logistic regression model was developed based on the selected factors influencing ciponv. the discrimination of the model was assessed by the rocauc and the goodness of fit of the model was evaluated using the hosmer-lemeshow test and calibration plots. a nomogram based on the logistic regression model output was developed as a tool for clinical application.

Eligibility criteria:
inclusion criteria: a) age between 18 and 75 years, b) having 3 or 4 apfel risk factors, and c) scheduled to undergo laparoscopic gastrointestinal surgical procedures under general anesthesia. exclusion criteria: a) american society of anesthesiologists (asa) physical status greater than 3, b) severe hepatic dysfunction, c) contraindications to fosaprepitant, 5-ht3 receptor antagonist, or dexamethasone, d) preoperative use of medications known to have antiemetic properties, e) presence of mental disorders or inability to communicate, and f) pregnant or nursing women.
effects of joint effusion on quadriceps muscle

Conditions: Knee Osteoarthritis

Summary: the present study investigated whether the presence of fluid in the joint affected peak torque and the root mean square (rms) values of surface electromyography (emg) in patients symptomatic for osteoarthritis (oa).

several studies have shown that knee effusion influenced quadriceps muscle activity and induced quadriceps arthrogenic muscle inhibition in normal volunteers. however, the effect of joint effusion on the quadriceps of patients with oa is controversial,and few patients with oa have been included in studies of joint effusion.

Eligibility criteria:
inclusion criteria: * 50 years old or older with knee osteoarthritis * knee pain without joint effusion confirmed by ultrasonography exclusion criteria: * the presence of knee joint effusion determined using us * a history of knee injury or surgery * a history of knee injection within 3 months * a history of inflammatory arthritis * taking anticoagulants * balance or gait disturbance * diabetes mellitus

Keywords: knee osteoarthritis effusion.
the efficacity of hemodiafiltration versus hemofiltration for renal insufficiency during intensive care

Conditions: Renal Failure, Acute

Summary: the primary objective of this study is to compare the efficacity of hemodiafiltration and hemofiltration for decreasing plasma urea at 12h among intensive care patients. secondary objectives include comparing urea clearance, filter duration, and %down-time, between the two techniques.


Eligibility criteria:
inclusion criteria: * according to rifle score, patient is stage 'f' * the patient must be insured or beneficiary of a health insurance plan * the patient meets at least one of the following criteria: * metabolic acidosis (ph \< 7.2), excluding keto-acidosis * plasma urea \> 25 mmol/l * hyper-hydration is not controlled by diuretics exclusion criteria: * chronic, terminal renal insufficiency with dialysis * the patient is under judicial protection, under tutorship or curatorship * suspect hyperkaliemia (kaliemia \> 6.5 mmol/l with electrocardiographic effects) * intoxications treated via dialysis * pregnant, lactating, parturient women * medical indication for localized citrate anticoagulation * dialysis of less than 12 h * patient or representative refuses to participate
pharmacokinetics and safety study with alfuzosin in children and adolescents with elevated detrusor leak point pressure of neuropathic etiology

Conditions: Urinary Bladder Neurogenic

Summary: the primary objective is to investigate the pharmacokinetics (pk) of 2 doses of alfuzosin (given as a solution or tablets depending on age) in children and adolescents 2 to 16 years of age with elevated detrusor leak point pressure (lpp) (≥40 cm h2o) of neuropathic etiology stratified into 2 age groups (2 to 7 years and 8 to 16 years). the secondary objectives are to investigate the safety and tolerability of the 2 dose regimens and to determine the effect of the 2 dose regimens on detrusor lpp.


Eligibility criteria:
inclusion criteria: * children and adolescents of either gender 2-16 years of age with elevated detrusor lpp of neuropathic etiology.

Keywords: elevated detrusor leak point pressure
coping and post traumatic distress in children and adolescents during cancer follow-up care

Conditions: Pediatric Cancer; Follow-up Care

Summary: to explore the presence of post traumatic disorder and its association with coping strategies in children and adolescents during cancer follow-up care. hypothesis: the investigators expect a reduction of post traumatic symptoms according to adequate coping strategies (eg. approach coping styles).

oncological disease in childhood or adolescence can represent a highly traumatic experience, considering its physical, psychological and social consequences in the short and long term. the literature has investigated this population both in the acute phase of the disease and at the end of the therapies to explore the potentially traumatic effects of this experience. while some studies support the non-incidence of post-traumatic symptoms related to the disease and underline a post-traumatic growth, other studies confirm a high risk of developing post-traumatic symptoms. this risk increases according to specific demographic (eg. age of diagnosis) and clinical (eg. type of disease, of treatments, etc.) characteristics. the literature also points out that these consequences can be mediated by some factors, including coping strategies, that is the way patients manage stress. the study aims: to investigate the presence of post-traumatic symptoms in patients out of therapy and in follow-up care; to explore the possible association between this post-traumatic symptomatology and the coping strategies used by the patients; to focus the possible correlation between post traumatic symptoms, coping and the demographic and clinical characteristics of patients.

Eligibility criteria:
inclusion criteria: * patients in cancer follow-up care since less than 3 years * scheduled to follow-up appointement * italian speaking * patients' and parents' consent exclusion criteria: - cognitive and/or developmental impairment

Keywords: post-traumatic stress coping pediatric cancer follow-up
peri-operative lidocane, ketamine, or lidocane and ketamine combination, infusion for patients undergoing spine surgery

Conditions: Postoperative Pain

Summary: this study has been designed as a controlled clinical trial to evaluate the efficacy of brief lidocaine infusion, brief ketamine infusion and a lidocaine/ketamine combined infusion when added to conventional opioid therapy following major spine surgery, as well as to evaluate the effects of the lidocaine/ketamine pain protocol on the feasibility of performing routine intraoperative neurophysiology during spine surgery in adults and determine whether this infusion protocol is compatible with intraoperative neurophysiology on spine surgery patients. if one or more of the approaches is confirmed as efficacious and safe, it could have a significant impact on the routine management of postoperative pain in this context.


Eligibility criteria:
inclusion criteria: male and female \>/= 18 years of age patients undergoing first-time fusion surgery or surgery to revise a prior fusion able to read, write and speak in english, and able to give informed consent for the study exclusion criteria: any disease associated with major organ dysfunction renal dysfunction hepatic dysfunction cardiac dysfunction
continuous glucose monitoring (cgm) in subjects with type 2 diabetes taking twice-daily exenatide or once-weekly exenatide

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this substudy is to obtain cgm data from individuals taking exenatide. the cgm measurements gathered before starting and during treatment with exenatide ir and/or exenatide lar will help determine the characteristics of glucose control during treatment.


Eligibility criteria:
inclusion criteria: * participant in amylin protocol 2993lar-105 * at least 16 years of age * type 2 diabetes being treated with stable regiment of metformin, su, tzd, combination of metformin/su, combination metformin/tzd, combination su/tzd * a1c 7.1 - 11 * fasting glucose less than 280 at screening * bmi 25 - 45 * stable body weight 6 months prior to screening * not pregnant and willing to practice birth control * physical exam \& ecg not clinically significant * lab values judged not to be clinically significant * able to understand \& sign consent form exclusion criteria: * clinically significant medical condition as judged by investigator * drug or alcohol abuse * previous use of exenatide or any glp-1 analog * has used any investigational drug in the past 30 days prior to screening * is currently using: alpha-glucosidase inhibitor, insulin, drugs that affect gi motility, use of systemic corticosteroids, use of medications with addictive potential, prescription or otc weight-loss medications * has donated blood within 60 days of screening, or is planning to donate during the study * has had major surgery or blood transfusion within 2 months of screening * has had a surgical procedure that may impact gastric emptying * has any allergies or hypersensitivity to any component of study treatment * is an immediate family member of personnel affiliated with the study at the investigative site * is employed by amylin, lilly or alkermes

Keywords: exenatide twice daily or once weekly continuous glucose monitoring
qualification of point-of-care assays for management of hcv patients

Conditions: Hepatitis C

Summary: acute or chronic hcv infection can lead to liver complications, including liver failure, cirrhosis or liver cancer. for patients with hepatitis c infection, the major clinical question remains the terms of treatment initiation. in europe, new treatments are available since the approval of three direct acting antivirals. however with the high cost of these treatments, they are currently only available for critically ill patients. other molecules are currently in advanced clinical development phases. the use of clinical predictors remains relevant for the selection of a suitable treatment for each patient, in particular to limit the adverse effects and reduce costs. currently the quantification of viral load is a measure of response to treatment; with the recommendation to stop treatment in patients who fail to achieve an undetectable level of viral load. genetic factors have also been identified as predictors of response to treatment, in particular polymorphisms of the il-28b gene. genotyping of this gene is currently performed using classical pcr amplification applied to dna extracted from blood, with a time to result of 2-3 weeks. we propose in this protocol to test a non-invasive method and rapid test for il-28b genotype which could be used for point of caring testing, and ultimately better patient management. this is a monocenter, cross-sectional study among hcv chronic patients. the study will be conducted in 250 hcv patients, all viral genotypes combined, at cochin hospital (paris, france). objectives the principal objective is to assess the accuracy of the newly developed point-of-care genotyping assay (genedrive® il-28b assay) to detect in hcv patients the genotype cc versus non cc (i.e. ct and tt) against the taqman allelic discrimination assay as gold standard. the secondary objective is to assess the concordance between the genotype results of the genedrive and the gold standard regarding the three genotypes cc, ct and tt.


Eligibility criteria:
inclusion criteria: * age \> 18 years old. * patients diagnosed with hepatitis c (all viral genotypes). * patient already treated or recommended to start antiviral therapy against hepatitis c virus or currently undergoing antiviral therapy. * patients who consented to il-28b genotyping in the course of their usual follow-up by conventional pcr standard method. * patients affiliated to social security. * informed consent must be obtained for all subjects prior to study entry. exclusion criteria: * a person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure.

Keywords: vhc il28-b point of care
clinical features associated with restless legs syndrome.

Conditions: Restless Legs Syndrome

Summary: restless legs syndrome (rls) is a chronic neurological disorder characterized by an urge to move the legs at night when at rest. rls can lead to a sleep deprivation, increased falling risk, daytime sleepiness, depression and decreased quality of life. dopamine agonists, alpha-2-delta ligands and opiates are key medications for rls. the natural course of rls is very heterogeneous with a risk of increasing the severity of symptoms over the years despite the use of drugs and recommended dosages. many comorbidities can make rls worse. augmentation syndrome is the main complication of dopamine agonists. however, only a few studies have addressed the clinical, biological and pharmacological factors associated with the evolution of the severity of rls. the objective of this study is to assess the evolution of rls symptoms severity as function of rls phenotype, comorbidities and rls medication, in large cohort of members of the french rls association and other european rls association.

in this study, the investigators want to study the clinical course of rls in a population of rls patients who are members of the rls patient association, taking into account clinical and biological factors as well as the treatments taken for rls.

Eligibility criteria:
inclusion criteria: * adults subjects * restless legs syndrome diagnosis * member of the restless legs syndrome association * french speaking * able to understand the study * signed written informed consent * affiliated to social security exclusion criteria: - vulnerable subject : subject deprived of liberty or protected by law (trusteeship, legal guardianship)

Keywords: restless legs syndrome augmentation syndrome dopamine agonists alpha 2 delta ligands opiates
analysis of radiological features of lateral femoral impaction fracture / lateral femoral notch sign

Conditions: Anterior Cruciate Ligament Injuries; Anterior Cruciate Ligament Rupture; Anterior Cruciate Ligament Tear

Summary: analysis of radiological features of lateral femoral impaction fracture (lfc-if) / lateral femoral notch sign will be performed on mris of consecutive patients after anterior cruciate ligament (acl) injuries and without acl injuries.

two independent measurers will twicely measure the radiological features of lateral femoral impaction fracture / lateral femoral notch sign on mris of consecutive patients after anterior cruciate ligament (acl) injuries and without acl injuries. in cases without acl injuries, radiological features of terminal sulcus (ts), a native sulcus located on the lateral femoral condyle, will be measured. intra- and inter-rater agreements will be calculated. the following radiological features will be assessed/ measured: 1. presence of lfc-if/ ts 2. lfc-if/ ts depth 3. lfc-if/ ts length 4. distance from blumensaat line to the front border of lfc-if / ts 5. distance from blumensaat line to the deepest part of lfc-if / ts 6. distance from blumensaat line to the rear border of lfc-if / ts

Eligibility criteria:
inclusion criteria: * performed knee mri with or without acl tear exclusion criteria: * osteophytes hindering assessment of lfc-if/ ts morphology * morphological disturbances hindering assessment of lfc-if/ ts morphology
evaluation of stargraft-3 for hemodialysis

Conditions: End Stage Renal Disease

Summary: this study is a single site, prospective, single arm evaluation of the safety and effectiveness of the healionics stargraft-3 hemodialysis access graft. stargraft devices have been demonstrated in preclinical and other studies to have improved resistance to the common failure modes of venous anastomosis stenosis and infection. this study is an extension from prior studies with stargraft av (nct03916731) and stargraft-2 (nct04783779) investigational devices. a previous study also included control implants of commercially available standard eptfe grafts approved for the same use. the study is enrolling patients with end stage renal disease (esrd) requiring hemodialysis via a prosthetic vascular graft. the study proposes to evaluate the performance of the investigational stargraft-3 compared to the eptfe controls in the prior study and to published results, over a period of 6 months, with extended results to 1 year. estimated enrollment is 15 subjects in this study.


Eligibility criteria:
inclusion criteria: 1. male or female, \> 18 years or age. 2. patient has given informed consent to participate in the trial. 3. stated willingness to comply with all study procedures and availability for the duration of the study. 4. able to effectively communicate with study personnel. 5. candidate for a new arterio-venous graft placed in the upper arm. 6. life expectancy judged to be at least 2 years. 7. axillary vein of greater than or equal to 7 mm in diameter. 8. brachial artery of greater than or equal to 4 mm in diameter. 9. acceptable cardiac risk level (cardiac output ≥ 3.5 l/min, pulmonary artery pressure ≤ 50 mmhg, ejection fraction ≥ 40%) 10. systolic blood pressure equal to or greater than 120 mmhg. 11. absence of central venous stenosis downstream from implant site confirmed with ultrasound and/or venogram. exclusion criteria: 1. unable or unlikely to comply with trial protocol and/or follow-up. 2. pregnancy. 3. clinically morbid obesity. 4. anatomical limitations. 5. immunodeficiency syndrome. 6. history of bacterial infection within 8 weeks prior to graft implantation. 7. history of hypercoagulation or bleeding disorders. 8. elevated platelet count \> 1 million per microliter of blood. 9. history of heparin-induced thrombocytopenia syndrome (hit). 10. medically confirmed stenosis of the veins downstream of the implant site. 11. inadequate arterial flow or pressure proximal to the implant site. 12. currently participating in another investigation drug or device study which may clinically interfere with any endpoints of this trial. 13. fever greater than 38°c. 14. prior allergic reaction to silicone. 15. confirmed or suspected covid-19 infection within 8 weeks prior to graft implant, or ongoing covid-19 symptoms.

Keywords: hemodialysis vascular access arterio-venous grafts (avg)